Drug Interactions

Image
Drug Interactions Photo Banner
Drug Interactions no padding

As oncology pharmacists, we know that one of the key needs of cancer patients is the avoidance and/or management of drug interactions related to anticancer therapies. Identification and management of potential and actual drug interactions can help to minimize adverse events and maximize the intended impact of cancer treatments, supportive care agents and pharmacotherapy for additional co-morbidities.

Drug Interactions Resources

Participants in the Drug Interactions Workshops work through case studies typical of clinically relevant drug interactions they encounter in oncology pharmacy practice. Before participants arrive at the Workshop, they are asked to review relevant literature, either sourced online or via webinars created by CAPhO members. Members, log in to access the Drug Interactions Resources.

Members - Access Drug Interactions Resources

 

Drug Interactions Module Task Force and Support Team

2022 Drug Interactions Module Task Force members:

  • Nikki Blosser (Chair)
  • Kyla Bailey
  • Tina Crosbie
  • Nadine Glynn
  • Nicole Kennedy
  • Michelle Koberinski
  • Colleen Thurber
  • Jennifer Voisey
  • Jason Wentzell 

Support Team members:

  • Sea to Sky Meeting and Association Management Inc., Administrative Support
  • Mark Stephens, Windward Design Group, Graphic Designer

Disclaimer

Oncology’s Drug Interactions Program Disclaimer

The Canadian Association of Pharmacy in Oncology’s Drug Interactions Program has been designed to provide a general overview of oncology drug pharmacology and therapeutics. It is NOT intended to be a comprehensive reference and as such, it does NOT provide detailed explanations of mechanisms of action, descriptions of all drug indications, or an in-depth review of all possible adverse effects or drug interactions. The information contained in the Drug Interactions Program is not intended to be used to direct patient care decisions. It is important to utilize appropriate comprehensive resources, applicable primary literature and clinical judgment when making decisions regarding patient care.

CAPhO is not liable for any information provided in the content of the Drug Interactions Program. CAPhO hereby disclaims all liability for any claims, losses or damages in connection with use or application of these materials.

The content of the Drug Interactions cases is for educational purposes only and may contain some copyrighted materials from biology textbooks, medical periodicals, articles and websites. Wherever possible, the authors of such materials have been contacted for permission to use and/or adapt such materials; a reference or link is provided to the original source.

This educational initiative was funded by CAPhO. It has received no financial or in-kind support from any commercial or other organization.

CAPhO would like to acknowledge BC Cancer in allowing oncology pharmacists access to its online “Drug Interactions Module,” which is Phase 1 of this three-phased Drug Interactions Program.